Scholarlink

<p>Colony-stimulating factor 1 receptor (CSF1R), primarily expressed on microglia in the central nervous system (CNS), is essential for microglial homeostasis and survival. CSF1R dysfunction, due to a monoallelic mutation, causes CSF1R-related leukoencephalopathy (CRL), a primary microgliopathy. CSF1R undergoes proteolytic cleavage to release soluble CSF1R (sCSF1R), which is decreased in the serum of CRL patients. However, the biological function of sCSF1R remains unknown. Here, we found that sCSF1R alleviated cognitive impairment and anxiety-like behavior in <i>Csf1r</i><sup><i>+/−</i></sup> mice. Importantly, we identified CSF1R as a target binding protein of sCSF1R on microglia. Notably, sCSF1R inhibited the activation and inflammatory factor expression of <i>Csf1r</i><sup><i>+/−</i></sup> microglia by reducing the phosphorylation of CSF1R (Y723) and NF-κB (S468 and S536). These results demonstrate that sCSF1R exerts neuroprotective effects by binding membrane-bound CSF1R and inhibiting pathological microglial activation by inhibiting the nuclear translocation of NF-κB. These findings identify sCSF1R as a potential therapeutic agent for CRL.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Soluble CSF1R alleviates microgliopathy in a CSF1R-related leukoencephalopathy (CRL) mouse model

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月5日

查看全文
  • Yuhang Zhou,
  • Banglian Hu,
  • Jie Luo,
  • Xingyi Wang,
  • Xiaohua Huang,
  • Yanfang Li,
  • Xian Zhang,
  • Guojun Bu,
  • Hongsheng Zhang,
  • Yun-Wu Zhang,
  • Honghua Zheng

摘要

Colony-stimulating factor 1 receptor (CSF1R), primarily expressed on microglia in the central nervous system (CNS), is essential for microglial homeostasis and survival. CSF1R dysfunction, due to a monoallelic mutation, causes CSF1R-related leukoencephalopathy (CRL), a primary microgliopathy. CSF1R undergoes proteolytic cleavage to release soluble CSF1R (sCSF1R), which is decreased in the serum of CRL patients. However, the biological function of sCSF1R remains unknown. Here, we found that sCSF1R alleviated cognitive impairment and anxiety-like behavior in Csf1r+/− mice. Importantly, we identified CSF1R as a target binding protein of sCSF1R on microglia. Notably, sCSF1R inhibited the activation and inflammatory factor expression of Csf1r+/− microglia by reducing the phosphorylation of CSF1R (Y723) and NF-κB (S468 and S536). These results demonstrate that sCSF1R exerts neuroprotective effects by binding membrane-bound CSF1R and inhibiting pathological microglial activation by inhibiting the nuclear translocation of NF-κB. These findings identify sCSF1R as a potential therapeutic agent for CRL.